Aurinia Pharmaceuticals Inc
F:IKAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aurinia Pharmaceuticals Inc
F:IKAP
|
CA |
|
T
|
Travis Perkins PLC
OTC:TPRKY
|
UK |
|
M
|
Mosaic Co
F:02M
|
US |
|
Telenor ASA
F:TEQA
|
NO |
|
F
|
Flutter Entertainment PLC
F:PPB
|
IE |
|
Galatasaray Sportif Sinai ve Ticari Yatirimlar AS
IST:GSRAY.E
|
TR |
|
Banco Comercial Portugues SA
F:BCPN
|
PT |
|
E
|
E ON SE
DUS:EOAN
|
DE |
|
F
|
Flowserve Corp
XMUN:FWV
|
US |
|
Ziff Davis Inc
NASDAQ:ZD
|
US |
|
Aptus Value Housing Finance India Ltd
NSE:APTUS
|
IN |
|
Compania de Minas Buenaventura SAA
F:MBU
|
PE |
|
B
|
Bursa Malaysia Bhd
KLSE:BURSA
|
MY |
|
P
|
PG&E Corp
F:PCG
|
US |
|
CleanBnB SpA
MIL:CBB
|
IT |
|
R
|
Ryder System Inc
DUS:RYD
|
US |
|
H
|
Hochtief AG
XHAM:HOT
|
DE |
|
C
|
Clariant AG
F:CLRN
|
CH |
|
A
|
Assetwise PCL
SET:ASW
|
TH |
|
Delta Dunia Makmur Tbk PT
IDX:DOID
|
ID |
|
G
|
Galan Lithium Ltd
F:9CH
|
AU |
|
Roche Bobois SA
F:5RO
|
FR |
|
I
|
Ipsos SA
XMUN:IPZ
|
FR |
|
B
|
Bilibili Inc
OTC:BLBLF
|
CN |
Wall St Price Targets
IKAP Price Targets Summary
Aurinia Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for IKAP is 10.13 EUR with a low forecast of 8.85 EUR and a high forecast of 12.88 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IKAP's stock price target?
Price Target
10.13
EUR
According to Wall Street analysts, the average 1-year price target for IKAP is 10.13 EUR with a low forecast of 8.85 EUR and a high forecast of 12.88 EUR.
What is the Revenue forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
16%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 16%.
What is the Gross Profit forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
22%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 33%. The projected CAGR for the next 3 years is 22%.
What is the Operating Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
24%
The compound annual growth rate for Operating Income over the next 8 years is 24%.
What is the Pre-Tax Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
33%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 33%.
What is the Net Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
6%
The compound annual growth rate for Net Income over the next 8 years is 6%.
